Saskia Burridge
YOU?
Author Swipe
View article: Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme Open
CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) management and outcomes, but following CAR T infusion, interventions are often needed. In a UK multicentre study, we retros…
View article: Practice guideline: Preparation for <scp>CAR</scp> T‐cell therapy in children and young adults with <scp>B‐acute</scp> lymphoblastic leukaemia
Practice guideline: Preparation for <span>CAR</span> T‐cell therapy in children and young adults with <span>B‐acute</span> lymphoblastic leukaemia Open
Summary The objective of this guideline, prepared by the ALL subgroup of the Advanced Cell Therapy Sub‐Committee of BSBMTCT (British Society of Blood and Marrow Transplantation), is to provide healthcare professionals with practical guidan…
View article: S111: TREATMENT OF POST-TRANSPLANT RELAPSE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH BCP ALL USING CD19-CAR-T: A EUROPEAN RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
S111: TREATMENT OF POST-TRANSPLANT RELAPSE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH BCP ALL USING CD19-CAR-T: A EUROPEAN RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA Open
Background: Relapse after allogeneic hematopoietic stem cell transplantation (SCT) for very high-risk acute lymphoblastic leukemia (ALL) has a dismal prognosis. The potentially curative effect of a second SCT is jeopardized by a high rate …
View article: CD34<b>+</b>-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
CD34<b>+</b>-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy Open
2][3][4] Prolonged cytopenias are an underrecognized toxicity of CAR T-cell therapy.For example, in the ELIANA study, 41% and 53% of patients demonstrated grade 3 to 4 thrombocytopenia and neutropenia, respectively, persisting beyond day 3…